Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

Opinion
Video

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

Related Videos
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Ibrahim Aldoss, MD
Roger Li, MD, of Moffitt Cancer Center